A UK spinout company, Kesios Therapeutics Ltd, has obtained £19 million in Series A financing to develop therapies targeting a complex that is downstream from a protein implicated in many cancers. The lead candidate is for multiple myeloma. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
